Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor κB kinase

Translational Cancer Research

Volumn 1, Issue 2, 2012, Pages 100-108

  Shao, Lijian ^a   Wu, Lixian ^a,b   Zhou, Daohong ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; DNA double strand break; IKK ; Ionizing radiation; NF B

Indexed keywords

ANTINEOPLASTIC AGENT; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; SENSITIZATION; TRANSCRIPTION INITIATION; TUMOR CELL;

EID: 84962646360     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2012.05.04     Document Type: Review

References (62)

1. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
2. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738-47.
3. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
4. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
5. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13:1076-82.
6. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40.
7. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805:167-80.
8. Wu ZH, Shi Y, Tibbetts RS, et al. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006;311:1141-6.
9. Wu ZH, Miyamoto S. Many faces of NF-kappaB signaling induced by genotoxic stress. J Mol Med 2007;85:1187-202.
10. Gupta SC, Sundaram C, Reuter S, et al. Inhibiting NFkappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;1799:775-87.
11. Hinz M, Stilmann M, Arslan SC, et al. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell 2010;40:63-74.
12. Wu ZH, Wong ET, Shi Y, et al. ATM-and NEMOdependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell 2010;40:75-86.
13. Israël A. The IKK complex, a central regulator of NFkappaB activation. Cold Spring Harb Perspect Biol 2010;2:a000158.
14. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009;19:404-13.
15. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NFkappaB signaling pathways. Nat Immunol 2011;12:695-708.
16. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986;47:921-8.
17. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene 1999;18:6845-52.
18. Wang CY, Mayo MW, Baldwin AS Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996;274:784-7.
19. Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 2003;289:27-35.
20. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000;19:4159-69.
21. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001;20:859-68.
22. Guo J, Verma UN, Gaynor RB, et al. Enhanced chemosensitivity to irinotecan by RNA interferencemediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004;10:3333-41.
23. Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004;279:23477-85.
24. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007;67:3853-61.
25. Mi J, Zhang X, Rabbani ZN, et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008;16:66-73.
26. Yamagishi N, Miyakoshi J, Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells. Int J Radiat Biol 1997;72:157-62.
27. Bradbury CM, Markovina S, Wei SJ, et al. Indomethacininduced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res 2001;61:7689-96.
28. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183-93.
29. Kim KM, Zhang Y, Kim BY, et al. The p65 subunit of nuclear factor-kappaB is a molecular target for radiation sensitization of human squamous carcinoma cells. Mol Cancer Ther 2004;3:693-8.
30. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res 2008;14:2128-36.
31. Ewald JA, Desotelle JA, Wilding G, et al. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010;102:1536-46.
32. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001;4:303-13.
33. Jin F, Liu X, Zhou Z, et al. Activation of nuclear factorkappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 2005;65:6354-63.
34. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004;13:853-65.
35. Hsu SC, Gavrilin MA, Lee HH, et al. NF-kappa B-dependent Fas ligand expression. Eur J Immunol 1999;29:2948-56.
36. Feng G, Li Y, Bai Y. Induction of Fas receptor and Fas ligand by nodularin is mediated by NF-kappaB in HepG2 cells. Toxicol Appl Pharmacol 2011;251:245-52.
37. Hu MC, Lee DF, Xia W, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004;117:225-37.
38. Tezil T, Bodur C, Kutuk O, et al. IKK-beta mediates chemoresistance by sequestering FOXO3; A critical factor for cell survival and death. Cell Signal 2012;24:1361-8.
39. Irelan JT, Murphy TJ, DeJesus PD, et al. A role for IkappaB kinase 2 in bipolar spindle assembly. Proc Natl Acad Sci USA 2007;104:16940-45.
40. Blazkova H, von Schubert C, Mikule K, et al. The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions. Cell Cycle 2007;6:2531-40.
41. Xia Y, Padre RC, De Mendoza TH, et al. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA 2009;106:2629-34.
42. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8:193-204.
43. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008;18:80-6.
44. Wu L, Shao L, An N, et al. IKKbeta regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS One 2011;6:e18447.
45. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NFkappa B-dependent transcription in mice. J Biol Chem 2003;278:1450-6.
46. Kenneth NS, Mudie S, Rocha S. IKK and NF-kappaBmediated regulation of Claspin impacts on ATR checkpoint function. EMBO J 2010;29:2966-78.
47. Saeki T, Ouchi M, Ouchi T. Physiological and oncogenic Aurora-A pathway. Int J Biol Sci 2009;5:758-62.
48. Suzuki K, Verma IM. Phosphorylation of SNAP-23 by IkappaB kinase 2 regulates mast cell degranulation. Cell 2008;134:485-95.
49. Tsuchiya Y, Asano T, Nakayama K, et al. Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell 2010;39:570-82.
50. Ahmed KM, Li JJ. ATM-NF-kappaB connection as a target for tumor radiosensitization. Curr Cancer Drug Targets 2007;7:335-42.
51. Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008;14:5656-62.
52. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003;13:2419-22.
53. Wen D, Nong Y, Morgan JG, et al. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 2006;317:989-1001.
54. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NFkappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000;275:36062-6.
55. Kwok BH, Koh B, Ndubuisi MI, et al. The antiinflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001;8:759-66.
56. Cilloni D, Messa F, Arruga F, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006;20:61-7.
57. Yemelyanov A, Gasparian A, Lindholm P, et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006;25:387-98.
58. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
59. Yang J, Amiri KI, Burke JR, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 2006;12:950-60.
60. Gillooly KM, Pattoli MA, Taylor TL, et al. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. J Pharmacol Exp Ther 2009;331:349-60.
61. Townsend RM, Postelnek J, Susulic V, et al. A highly selective inhibitor of IkappaB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection. Transplantation 2004;77:1090-4.
62. McIntyre KW, Shuster DJ, Gillooly KM, et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003;48:2652-9.